Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions
MetadataShow full item record
Because of its multifaceted anti-inflammatory and immunomodulatory effects, delivering type-I interferon to Kupffer cells has the potential to function as a novel type of therapy for the treatment of various types of hepatitis. We report herein on the preparation of a Kupffer cell targeting type-I interferon, an albumin-IFNa2b fusion protein that contains highly mannosylated N-linked oligosaccharide chains, Man-HSA(D494N)-IFNa2b, attached by combining albumin fusion technology and site-directed mutagenesis. The presence of this unique oligosaccharide permits the protein to be efficiently, rapidly and preferentially distributed to Kupffer cells. Likewise IFNa2b, Man-HSA(D494N)-IFNa2b caused a significant induction in the mRNA levels of IL-10, IL-1Ra, PD-L1 in RAW264.7 cells and mouse isolated Kupffer cells, and these inductions were largely inhibited by blocking the interferon receptor. These data indicate that Man-HSA(D494N)-IFNa2b retained the biological activities of type-I interferon. Man-HSA(D494N)-IFNa2b significantly inhibited liver injury in Concanavalin A (Con-A)-induced hepatitis model mice, and consequently improved their survival rate. Moreover, the post-administration of Man-HSA(D494N)-IFNa2b at 2?h after the Con-A challenge also exerted hepato-protective effects. In conclusion, this proof-of-concept study demonstrates the therapeutic effectiveness and utility of Kupffer cell targeting type-I interferon against hepatitis via its anti-inflammatory and immunomodulatory actions.
Showing items related by title, author, creator and subject.
Decreased IP-10 and elevated TGFß1 levels are associated with viral clearance following therapy in patients with hepatitis C virusLee, S.; Varano, J.; Flexman, J.; Cheng, W.; Watson, M.; Rossi, E.; Adams, L.; Bulsara, M.; Price, Patricia (2010)The role of pro-fibrogenic cytokines in the outcome of infections with hepatitis C virus (HCV) and the response to treatment with pegylated interferon-alpha (pegIFNa) and ribavirin remains unclear. To address this issue, ...
Immunopathogenesis of hepatic flare in HIV/hepatitis b virus (Hbv)-coinfected individuals after the initiation of Hbv-active antiretroviral therapyCrane, M.; Oliver, B.; Matthews, G.; Avihingsanon, A.; Ubolyam, S.; Markovska, V.; Chang, J.; Dore, G.; Price, Patricia; Visvanathan, K.; French, M.; Ruxrungtham, K.; Lewin, S. (2009)Background. The pathogenesis of and risk factors for hepatic flare (HF) after the initiation of hepatitis B virus (HBV)-active antiretroviral therapy (ART) in HIV/HBV-coinfected individuals is not well understood. Methods. ...
Decreased IFNI? production correlates with diminished production of cytokines by dendritic cells in patients infected with hepatitis C virus and receiving therapyHammond, T.; Lee, S.; Watson, M.; Flexman, J.; Cheng, W.; Price, Patricia (2011)Toll-like receptor (TLR) expression and the signalling pathways that lead to the production of accessory cytokines by antigen-presenting cells (APCs) both have potential to limit T-cell responses to viral antigens. Here, ...